• Company
• 'Leclaza’s 5 counts of clinical results' to be showcased
• by Son, Hyung-Min May 2, 2024 05:53am

• Company
• Yuhan earns KRW253.2B through licensing-out deals in 5 yrs
• by Chon, Seung-Hyun May 2, 2024 05:52am

• Policy
• 1488 drugs approved last year…30% diabetes drugs
• by Lee, Hye-Kyung May 2, 2024 05:52am

• Policy
• 32 med schools in KOR confirm their admission quota
• by Lee, Jeong-Hwan May 2, 2024 05:52am

• Policy
• Gov’t will announce preferential pricing measures by June
• by Lee, Jeong-Hwan May 2, 2024 05:52am

• Policy
• Industry fumes over government's drug price reeval plan
• by Lee, Tak-Sun Apr 30, 2024 05:50am

• Policy
• Cancellation of Forxiga approval, HK inno.N gets indication
• by Lee, Tak-Sun Apr 30, 2024 05:50am

• Company
• Market withdrawal and indication transfer
• by Kim, Jin-Gu Apr 30, 2024 05:49am

• Company
• Clinical data on use of Repatha in Koreans revealed
• by Son, Hyung-Min Apr 30, 2024 05:49am

• Company
• Evolving ADC…pharma companies explore new DAC platform
• by Son, Hyung-Min Apr 30, 2024 05:49am